
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1



Joel M. Gelfand, MD, MSCE,^{a,b} April W. Armstrong, MD, MPH,^c Stacie Bell, PhD,^d
George L. Anesi, MD, MSCE, MBE,^{b,c} Andrew Blauvelt, MD, MBA,^f Cassandra Calabrese, DO,^g
Erica D. Dommasch, MD, MPH,^h Steve R. Feldman, MD, PhD,ⁱ Dafna Gladman, MD, FRCPC,^{j,k}
Leon Kircik, MD,^{l,m} Mark Lebwohl, MD,¹ Vincent Lo Re III, MD, MSCE,^{b,n} George Martin, MD,^o
Joseph F. Merola, MD, MMSc,^p Jose U. Scher, MD,^q Sergio Schwartzman, MD,^r James R. Treat, MD,^s
Abby S. Van Voorhees, MD,^t Christoph T. Ellebrecht, MD,^a Justine Fenner, MD,¹ Anthony Ocon, MD, PhD,^u
Maha N. Syed, MBBS,^a Erica J. Weinstein, MD,ⁿ Jessica Smith, BS,^d George Gondo, MA,^d Sue Heydon, MA,^d
Samantha Koons, BS,^d and Christopher T. Ritchlin, MD MPH^u
Philadelphia, Pennsylvania; Los Angeles, California; Portland, Oregon; Cleveland, Ohio; Boston, Massachusetts; Winston-Salem, North Carolina; Toronto, Ontario, Canada; New York and Rochester, New York; Indianapolis, Indiana; Maui, Hawaii; and Norfolk, Virginia

Objective: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.

Study design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.

Results: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.

Limitations: The evidence behind many guidance statements is limited in quality.

Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge. (J Am Acad Dermatol 2020;83:1704-16.)

From the Department of Dermatology,^a and the Department of Biostatistics, Epidemiology and Informatics and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia^b; the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles^c; the National Psoriasis Foundation, Portland^d; the Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia^e; Oregon Medical Research Center, Portland^f; the Department of Rheumatology and Immunology, Cleveland Clinic^g; the Department of Dermatology, Harvard Medical School, Boston^h; the Department of Dermatology, Wake Forest School of Medicine, Winston-Salemⁱ; the Krembil Research Institute, Toronto Western Hospital^j; the Psoriatic Arthritis Program, University Health Network, Toronto Western

Hospital, University of Toronto^k; the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York^l; Department of Dermatology, Indiana University Medical Center, Indianapolis^m; the Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphiaⁿ; Dermatology Associates, Maui^o; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston^p; the Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York^q; the Department of Rheumatology, Hospital for Special Surgery, New York^r; the Department of Pediatric Dermatology, Children's Hospital of Philadelphia^s; the Department of Dermatology, Eastern Virginia Medical School, Norfolk^t; and the Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester.^u

Key words: biologics; COVID-19; psoriasis; psoriatic arthritis; SARS-CoV-2.

Severe acute respiratory coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus that binds to the angiotensin-converting enzyme 2 receptor and causes the illness called coronavirus disease 2019 (COVID-19), has precipitated devastating personal, economic, and societal repercussions worldwide.¹⁻⁴ SARS-CoV-2 usually causes a mild, self-limited illness, but approximately 15% of affected individuals have a more severe, sometimes life-threatening course, with the risk of poor outcomes increasing with age and comorbidities.⁵⁻⁷ Diffuse alveolar damage and acute respiratory distress syndrome are the most common presentations in severe COVID-19. Additionally, thromboembolic events, along with direct and indirect viral-induced injury, may target the skin, gastrointestinal tract, kidney, heart, and brain, with devastating consequences.⁸⁻¹⁰

The type 1 interferon response, which is required to clear the virus, is often insufficient in the early phase of SARS-CoV-2 infection, but a

CAPSULE SUMMARY

- The National Psoriasis Foundation Coronavirus Disease-19 Task Force produced 22 guidance statements to promote optimal management of psoriatic disease during the pandemic.
- Shared decision making is recommended as is adherence to evidence-based recommendations when available. The guidance statements will be updated when necessary in accordance with rapidly evolving science of coronavirus disease 2019.

delayed persistent elevation may develop as the illness progresses.¹¹ Profound dysregulation of innate and acquired immunity can occur with more severe COVID-19, including significant lymphopenia as a direct result of viral-induced apoptosis and necrosis of lymphocytes in the spleen and lymph nodes.¹² The persistent interferon response can result in systemic hyperinflammation, also known as cytokine storm.^{13,14} Several of the cytokines elevated in severe

COVID-19 patients (tumor necrosis factor [TNF], interleukin 6, and interleukin 17) are also elevated in patients with psoriatic disease.¹⁵⁻¹⁷

The current model of COVID-19 is that immune suppression in early infection may be harmful by allowing uncontrolled SARS-CoV-2 replication and dissemination but may be helpful in severe illness by limiting organ damage from a dysregulated hyper-immune response.¹⁸ Many treatments used for psoriatic disease directly or indirectly impact immune pathways involved in COVID-19.¹⁹⁻²² Patients and

Funding sources: None.

Conflicts of interest: Dr Anesi has pending fees from UpToDate for authoring COVID-19 clinical reference material, and research time is supported by the Agency for Healthcare Research and Quality K12HS026372. Dr Armstrong has served as a research investigator and/or scientific advisor to LEO Pharma, AbbVie, UCB, Janssen, Eli Lilly and Company, Novartis, Ortho Dermatologics, Sun, Dermavant, BMS, Sanofi, Regeneron, Dermira, and Modmed. Dr Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie. Authors Bell, Gondo, Heydon, Koons, and Smith are employees of the National Psoriasis Foundation. Dr Calabrese is a speaker for Sanofi-Regeneron and a consultant for AbbVie. Dr Feldman received research, speaking, and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, LEO Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Quriient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. Dr Feldman also consults for others through

Guidepoint Global, Gerson Lehrman, and other consulting organizations, is the founder and majority owner of www.DrScore.com, and is also a founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis, Sanofi, Celgene, Ortho Dermatologics, and Pfizer, has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics, is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the *Journal of Investigative Dermatology*, receiving honoraria from the Society for Investigative Dermatology. Dr Gladman is a consultant for AbbVie, Amgen, BMS, Galapagos, Gilead, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB, and receives grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Dr Kircik has served as an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol-Myers Squibb, Boehringer Ingelheim, Cellcept, Celgene, Coherus, Dermavant, Dermira, Eli Lilly and Company, LEO Pharma, MC2, Maruho, Novartis, Ortho Dermatologics,

Abbreviations used:

CDC:	Centers for Disease Control and Prevention
COVID-19:	coronavirus disease 2019
NPF:	National Psoriasis Foundation
SARS COV-2:	severe acute respiratory coronavirus 2
TF:	task force
TNF:	tumor necrosis factor

providers are concerned about the safety of immunomodulating agents in the setting of the COVID-19 pandemic. These concerns are particularly relevant given that many of the comorbidities associated with psoriasis and psoriatic arthritis, including obesity, diabetes, and cardiovascular disease, are risk factors for the development of severe COVID-19.^{23,24} To address the questions posed by patients and providers, the National Psoriasis Foundation (NPF) commissioned a COVID-19 task force (TF) to develop scientifically based guidance that promotes optimal management of psoriatic disease during the pandemic.

METHODS

See the Online Supplement for detailed methods, available via Mendeley Data, V2, at <https://doi.org/10.17632/x4mxnjmc76>.

Establishment of the TF

The COVID-19 TF includes 18 physicians with a variety of expertise relevant to decision making in

the pandemic from different geographic areas within the United States and Canada, many of whom have frontline experience managing a surge of COVID-19 patients (Supplemental E-Table I, available via Mendeley Data, V1, at <https://doi.org/10.17632/2cbs7r7z72.1>). The TF was supplemented by nonvoting members, which included 4 trainees in dermatology, rheumatology, and infectious diseases, 1 postdoctoral fellow in epidemiology, as well as senior staff from the NPF.

Evidence synthesis

The TF co-chairs completed weekly literature searches for COVID-19 in relation to psoriatic disease. TF members also recommended papers of broad importance to COVID-19 related to its basic biology, epidemiology, and treatment. Additional sources of data were obtained from the Centers for Disease Control and Prevention (CDC), World Health Organization, the United States Food and Drug Administration, and the National Institutes of Health.

Development of clinical questions

The TF met every 2 weeks to discuss the developments in the literature and clinical experience. Clinical questions relevant to the psoriatic disease community were iterated and informed by questions received by the NPF from the broader patient and clinical community. The questions were subdivided into 5 categories, and work groups with balanced expertise were formed. Each TF work group convened to draft responses to the clinical questions

Pfizer, Dr. Reddy's Laboratories, Sun Pharma, UCB, Taro, and Xenoport. Dr Lebowitz is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB, and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis Inc, Avotres Therapeutics, BirchBioMed Inc, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica. Dr Martin is a consultant for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB, and is a scientific advisor for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB. Dr Merola is a consultant and/or investigator for Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Sun Pharma, Pfizer, and EMD Sorono. Dr Ritchlin reports personal fees from AbbVie, Amgen, Janssen, Novartis, UCB, and Boehringer Ingelheim, and grants from Amgen, UCB, and AbbVie outside the submitted work. Dr

Schwartzman is a speaker for AbbVie, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, and UCB, owns stock in Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer, is a consultant for AbbVie, Myriad, Janssen, Gilead, Eli Lilly and Company, Novartis, and UCB, is a scientific advisory board member for Myriad, and is a board member of the National Psoriasis Foundation. Dr Scher is a consultant for UCB, Janssen, AbbVie, Pfizer, Novartis, and Sanofi. Dr Syed is supported by a grant from Pfizer. Dr Van Voorhees has been an investigator for Celgene, Eli Lilly and Company, and AbbVie, and has been an advisor/consultant for AbbVie, Allergan, AstraZeneca, Celgene, Dermira, Merck, Novartis, Pfizer, UCB, and Valeant. Drs Weinstein, Ellebrecht, Ocon, Fenner, Treat, Dommasch, and Lo Re have no conflicts of interest to disclose.

IRB approval status: Not applicable.

Accepted for publication September 2, 2020.

Reprints not available from the authors.

Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA, 19104. E-mail: Joel.Gelfand@pennmedicine.upenn.edu.

Published online September 4, 2020.

0190-9622

© 2020 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2020.09.001>

based on the available evidence. These responses were reviewed and drafted into guidance statements.

Modified Delphi process

The guidance statements were presented to the 18 TF members using a modified Delphi process, including 2 rounds of voting with discussion in between. The Delphi approach was based on the RAND appropriateness method, which has been extensively validated.²⁵⁻³¹

TF members were asked to report their level of agreement anonymously with each guidance statement on a scale of 1 to 9. A rating of 1 corresponded to “complete disagreement,” 5 corresponded to “uncertain or neutral,” and 9 corresponded to “complete agreement.” The members were able to provide anonymous written comments. Median vote ratings of 1 to 3, 4 to 6, and 7 to 9 were defined a priori as disagreement, uncertainty/neutral, and agreement, respectively. Panel consensus was determined to be “low” when ≥ 5 votes fell into the 1 to 3 rating range with ≥ 5 votes concurrently falling into the 7 to 9 rating range. Consensus was interpreted as “high” if all 18 votes fell within a single tertile, with all other combinations considered as “moderate” levels of consensus. The results were analyzed by the NPF along with an independent analysis of the data by a nonvoting member of the TF, which yielded identical results.

RESULTS

The NPF COVID-19 TF Delphi was completed over a 2-week period (Supplemental E-Table II, available via Mendeley Data, V1, at <https://doi.org/10.17632/2cbs7r7z72>). Five categories of questions were explored (Supplemental E-Table III, available via Mendeley Data, V1, at <https://doi.org/10.17632/2cbs7r7z72>) with 100% complete voting on 22 guidance statements (Table I³² and Supplemental E-Table IV, available via Mendeley Data, V2, at <https://doi.org/10.17632/n78m9f3cpr>). The median was within the category of agreement for all statements, with the number of votes outside the range of agreement being only 1 or 2 for statements where agreement was not unanimous. All guidance statements were recommended, 9 with high consensus, and the remainder with moderate consensus.

Category 1: What are the effects of psoriatic disease itself on SARS-CoV-2 infection and COVID-19 illness?

Patients with psoriatic disease appear to have similar rates of infection with SARS-CoV-2 and COVID-19 outcomes³³⁻³⁷ as the general population (Guidance 1.1). However, uncertainty remains

regarding this question. First, a few reports suggest that patients with psoriasis may be more prone to infection with COVID-19 or have worse outcomes.³⁸⁻⁴⁰

For example, a United Kingdom study with more than 17 million patients found a small but statistically increased risk of death from COVID-19 (fully adjusted hazards ratio, 1.19; 95% confidence interval, 1.11-1.27) in individuals with psoriasis, rheumatoid arthritis, or lupus.³⁹ It is unknown from this study the degree to which the observed finding is driven by psoriasis, its severity, or treatment. Additionally, patients with psoriatic disease may be prone to thrombotic complications that can also occur in COVID-19.⁴¹⁻⁵⁵ There was unanimous agreement that severity of COVID-19 is driven by risk factors such as older age and comorbidities (Guidance 1.2).^{33,36,37,39,56-59} Psoriatic disease—particularly severe psoriasis—is associated with many of the comorbidities that drive COVID-19 mortality.^{45,49,60}

Category 2: What are the effects of psoriasis or psoriatic arthritis treatment on SARS-CoV-2 infection and COVID-19 illness?

The existing literature suggests that treatments for psoriasis or psoriatic arthritis, or both, do not meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes (Guidance 2.1).^{34,36,37,61-85} Cyclosporine, the most broadly immunosuppressive of psoriasis treatments, was not found to alter the risk of COVID-19 in 130 patients in Italy with psoriasis or atopic dermatitis (2 became infected with SARS-CoV-2 and recovered without hospitalization).⁷⁰ This study lacked a comparison group and was too small to reach definitive conclusions. One study suggested that patients with psoriasis on biologics were more likely to be hospitalized for COVID-19 but did not adjust for risk factors known to drive poor COVID-19 outcomes.⁸⁶

The rheumatology literature also suggests that treatments used for psoriatic disease, such as TNF inhibitors and methotrexate, do not negatively impact COVID-19,⁸⁷⁻⁹⁰ with 1 large registry (600 case reports from 40 countries) finding that TNF inhibitors are associated with a reduced adjusted odds of COVID-19 hospitalization compared with patients with rheumatic conditions not treated with TNF inhibitors.⁹⁰ Similarly, adverse effects of TNF inhibitors on COVID-19 were not observed in large registries of patients with inflammatory bowel disease.^{91,92} Small case series have reported poor COVID-19 outcomes in patients on Janus kinase inhibitors for psoriatic arthritis⁹³ and secukinumab for ankylosing spondylitis⁸⁹; however, these isolated reports could be due to selection bias, chance, or underlying comorbidity. By contrast, an analysis of approximately 1400 patients from the

Table 1. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Guidance #	Guidance statement	Level of consensus
1.1	It is not known with certainty whether having psoriatic disease meaningfully alters the risks of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course of COVID-19 illness. Existing data, with some exceptions, generally suggest that patients with psoriasis and/or psoriatic arthritis have similar rates of SARS-CoV-2 infection and COVID-19 outcomes as the general population.	Moderate
1.2	The likelihood of poor outcomes from COVID-19 is driven by risk factors such as older age and comorbidities, such as chronic heart, lung, or kidney disease, and metabolic disorders such as diabetes and obesity. Patients with psoriatic disease are more prone to these comorbidities, particularly in those with more severe disease.	High
2.1	It is not known with certainty whether treatments for psoriasis and/or psoriatic arthritis meaningfully alter the risks of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course of COVID-19 illness. Existing data generally suggest that treatments for psoriasis and/or psoriatic arthritis do not meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes.	Moderate
2.2	It is recommended that patients who are not infected with SARS-CoV-2 continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared decision making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see Guidance 2.5 for the definition of shared decision making).	High
2.3	Chronic systemic corticosteroids should be avoided if possible for the management of psoriatic arthritis. If patients require chronic systemic corticosteroids for management of psoriatic arthritis, the dose should be tapered to the lowest dose necessary to achieve the desired therapeutic effect. Chronic systemic corticosteroid use for the treatment of psoriatic disease at the time of acute infection with SARS-CoV-2 may be associated with worse outcomes from COVID-19 illness. It is important to note, however, that corticosteroids may improve outcomes for COVID-19 when initiated in hospitalized patients requiring oxygen treatment.	High
2.4	Individuals newly diagnosed with psoriasis and/or psoriatic arthritis or who are currently not receiving treatment should be aware that untreated psoriatic disease is associated with serious impact on physical and emotional health and, in the case of psoriatic arthritis, can lead to permanent joint damage and disability. Shared decision making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see Guidance 2.5 for shared decision making).	High
2.5	Providers recommend shared decision making with patients. Shared decision making between clinician and patient should be guided by several factors, including the potential benefits of treatment, the activity of skin and/or joint disease, and response to previous therapies, as well as the patient's underlying risk for poor COVID-19 outcomes and ability to maintain measures to prevent infection with SARS-CoV-2, such as hand hygiene, wearing of masks, and physical distancing, as required by pandemic conditions. A review of known benefits of treatment accompanied by acknowledgment of the uncertainty related to the COVID-19 pandemic and a discussion of a patient's individual circumstances and preferences should guide decision making.	Moderate
3.1	Telemedicine should be offered to manage patients wherever possible when local restrictions or pandemic conditions limit the ability for in-person visits. The following patients can be managed with telemedicine: Patients who are clinically stable and previously started on psoriatic disease treatment. Patients requiring a follow-up visit and refills for medication. New patients without timely access to in-person visits. Patients diagnosed with COVID-19 who are experiencing a significant flare. If telemedicine visits become inadequate to monitor patients' disease progress or manage new or evolving symptoms or signs of skin and joint disease, clinicians and patients should consider in-person visits.	Moderate
3.2	The following patients should be considered for in-person care if pandemic conditions allow (ie, the clinical practice is open to see patients in person): Patients at risk for melanoma and nonmelanoma skin cancer should be seen in person at a frequency consistent with standard of care for a full skin examination. New patients establishing care. Patients experiencing unstable psoriatic disease/flares. Patients requiring a thorough skin/or joint examination and a full physical examination for rheumatology patients.	Moderate

Continued

Table I. Cont'd

Guidance #	Guidance statement	Level of consensus
3.3	Providers recommend the recent guidelines published by Lim et al ³³ on how to optimize safety of office phototherapy for the patients and staff in the setting of the pandemic. See Table II for details.	High
4.1	Patients should be advised to follow measures that prevent infection with SARS-CoV-2. These preventative measures include to practice good hand hygiene, to maintain physical distancing from nonhousehold members, and to wear a face covering of the nose and mouth when indoors (except in their own home), and when outdoors but unable to maintain physical distancing. Face coverings should not be used in children under 2 years old due to risk of suffocation. See Supplemental E-Table VI for details.	High
4.2	Patients with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 in the work place. If the work place environment does not allow for maintenance of prevention measures, a shared decision-making process between the patient and his/her clinician is recommended to determine whether specific accommodations are medically necessary, especially for individuals who, due to age or underlying health conditions, are at especially high risk for poor COVID-19 outcomes.	Moderate
4.3	Youth with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 while at school. These measures include maintaining 6 feet of physical distancing, consistently wearing masks if over the age of 2 years, and washing hands frequently. If the school environment is unable to ensure these prevention measures or families believe their child may not be able to adhere to these practices, we encourage discussion with the patient, caregivers, and his/her clinician to collectively develop a learning plan in the best interest and safety of the child.	High
4.4.	Patients with psoriatic disease should receive the seasonal inactivated (eg, killed) influenza vaccine when it becomes available. While this vaccine will not protect against SARS-CoV-2, influenza vaccine lowers the risk of infection from seasonal influenza, which is of special importance to individual and public health during the COVID-19 pandemic. Patients taking systemic medications for psoriasis or psoriatic arthritis should discuss the timing of the influenza vaccination with respect to their systemic psoriatic medications with their health care provider in order to optimize the response to the influenza vaccine.	High
5.1	Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their symptoms and discuss the management of their treatments with their health care providers.	Moderate
5.2	Patients with psoriatic disease who become infected with SARS-CoV-2 should be prescribed and adhere to evidence-based COVID-19 therapies. Evidence-based therapies should be used, currently including supportive care for patients with mild disease, as well as dexamethasone (systemic corticosteroids) and remdesivir treatment, if available, for hospitalized patients requiring supplemental oxygen. The care of the hospitalized patient should include consultation with rheumatologists, dermatologists, and/or infectious disease specialists as medically necessary.	Moderate
5.3	Systemic corticosteroids for the management of COVID-19 in patients with psoriatic disease are not contraindicated and should not be withheld due to the concern of potentially flaring psoriasis upon withdrawal of corticosteroids when evidence demonstrates the effectiveness for treating COVID-19 illness.	Moderate
5.4	Hydroxychloroquine or chloroquine are not recommended for the prevention or treatment of COVID-19 in patients with psoriatic disease outside of a clinical trial. Cases of psoriasis flare have been reported in patients on antimalarial medications, but the clinical significance is not well understood.	High
5.5	Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis. Most patients can restart psoriasis and/or psoriatic arthritis treatments after complete resolution of COVID-19 symptoms. In those who have had a severe hospital course, shared decision making made on a case-by-case basis is recommended.	Moderate
5.6	Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare of psoriasis based on case reports. The clinical significance of the risk of COVID-19 flaring psoriasis is not known.	Moderate

Continued

Table I. Cont'd

Guidance #	Guidance statement	Level of consensus
5.7	Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance on home isolation and discuss with their health care providers when they can end home isolation. We recommend waiting a minimum of 10 days after COVID-19 symptom onset, along with fever resolution for 24 hours, without antipyretics, and improvement in other symptoms before ending home isolation and returning to work, as patients are unlikely to be infectious after this point. In patients with severe cases of COVID-19 or when patients with psoriasis are on medications with immunosuppressive effects, we recommend a case-by-case approach to determining the length of home isolation.	Moderate
5.8	Patients with close contact to someone with SARS-CoV-2 infection should quarantine themselves for 14 days after the last contact and discuss the management of their psoriatic disease treatment with their medical provider(s).	Moderate

CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

rheumatology, gastroenterology, and dermatology literature concluded that biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe COVID-19 outcomes.³³

Given these data, patients who are not infected with SARS-CoV-2 should continue their biologic or oral therapies for psoriasis or psoriatic arthritis in most cases (Guidance 2.2). Nevertheless, the existing literature is largely based on small case series or large registries of spontaneous reports, and therefore, shared decision-making between clinician and patient is recommended (Guidance 2.2, 2.4, and 2.5). By contrast, studies in the rheumatology and gastroenterology literature have observed that long-term use of oral corticosteroids is associated with worse COVID-19 outcomes (ie, hospitalization or a composite outcome of any or all of intensive care unit admission, ventilator use, or death).^{33,90,91} Chronic systemic corticosteroids should be avoided, if possible, for the management of psoriatic arthritis (Guidance 2.3).¹⁹

Category 3: How should medical care be delivered to patients with psoriatic disease to lower their risk of infection with SARS-CoV-2 while still ensuring quality of care?

The pandemic has disrupted the ability of patients and providers ability to meet in person due to personal protective equipment shortages, measures implemented to lower risk of SARS-CoV-2 transmission, and patients' personal and economic hardships.⁹⁴⁻⁹⁷ Patients express concern about being exposed to SARS-CoV-2 in the clinical setting either directly or indirectly (ie, on public transportation). Telemedicine can achieve similar outcomes for psoriasis patients compared with in-person care with a

dermatologist⁹⁸⁻¹⁰⁰; however, limited information is available on the management of psoriatic arthritis with telemedicine.^{32,101} Telemedicine should be considered when pandemic conditions limit in-person visits (Guidance 3.1).¹⁰² However, there are limitations of telemedicine, and therefore, some patients should be evaluated in person (Guidance 3.2). Office-based phototherapy remains an important option for patients with psoriasis (Guidance 3.3, Table II).^{103,104}

Category 4: What should patients with psoriatic disease do to protect themselves from becoming infected with SARS-CoV-2?

Patients should be advised to follow measures that prevent infection with SARS-CoV-2 (Guidance 4.1; E-Table VI, available via Mendeley Data, V2, at <https://doi.org/10.17632/w5m8jf94m8>).¹⁰⁵ These prevention measures should be followed at work (Guidance 4.2) and school (Guidance 4.3). In cases where measures to prevent transmission of SARS-CoV-2 at work or school cannot be maintained, shared decision making is recommended to determine whether specific accommodations are medically necessary (Guidance 4.2 and 4.3). Psoriasis, even when involving the face or hands, is not a contraindication to face coverings and hand washing, respectively, and a variety of approaches can be applied to mitigate skin irritation (E-Table VII, available via Mendeley Data, V2, at <https://doi.org/10.17632/w5m8jf94m8>).¹⁰⁶⁻¹⁰⁸ Patients with psoriatic disease should receive the seasonal inactivated (eg, killed) influenza vaccine, which is of special importance to individual and public health during the COVID-19 pandemic (Guidance 4.4). Providers may consider temporary discontinuation of methotrexate for 2 weeks after the influenza immunization to

Table II. Methods to reduce risk of SARS-CoV-2 transmission during delivery of office-based phototherapy*

Patient protocol	Staff protocol
• Screened for signs and symptoms of COVID-19 before entering the unit, understanding that treatment will be denied to symptomatic patients. • Attend the phototherapy appointment alone. Minors can be accompanied by a guardian, given all safety protocols are observed • Apply hand sanitizer upon entering and leaving the unit • Patient provided with goggles must sanitize them thoroughly, according to the manufacturer's instruction • Wear a mask, unless phototherapy treatment of the face is required • Practice physical distancing	• Schedule patients approximately 30 minutes apart per booth • Practice physical distancing, particularly in waiting area, with seats 6 feet apart. • Wear a mask, eye protection, and apply hand sanitizer before and after each patient encounter. • Avoid turning on the fan of the phototherapy unit if possible; if need be, treatment can be fractionated to avoid excessive heat build-up in the unit • Disinfect high-touch surfaces in the changing area after each patient • Disinfect high-touch area of the phototherapy equipment in between patients • Provide patients with disposable bags to store personal items • Provide goggles to patients if need be; ensuring they are sanitized thoroughly and stored in an individual bag

COVID-19, Coronavirus disease 2019; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2.

*Adapted from Lim et al.¹⁰³

improve the immunogenicity of the seasonal influenza vaccine.¹⁰⁹

Category 5: What should patients with psoriatic disease do if they become infected with SARS-CoV-2?

Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their symptoms (Supplemental E-Table VIII), discuss management of their psoriatic disease treatments with their health care providers, and should be prescribed and adhere to evidence-based COVID-19 treatments, if available (Guidance 5.1 and 5.2).^{85,110-112} The mortality benefit of initiation of corticosteroids in patients with severe COVID-19 outweighs the risks of potentially precipitating a psoriasis flare, and therefore, acute systemic corticosteroids are not contraindicated for the management of COVID-19 in patients with psoriatic disease (Guidance 5.3).^{112,113} On the basis of limited available data, and to be consistent with prescribing information, it may be prudent to hold treatments that target the immune system in the setting of suspected or confirmed SARS-CoV-2 infection, but the final decision needs to be determined on a case-by-case basis.

Consistent with guidance from the Food and Drug Administration and the American College of Physicians, the use of hydroxychloroquine or chloroquine is not recommended to prevent or treat COVID-19 in patients with psoriatic disease outside of a clinical trial (guidance 5.4).¹¹⁴⁻¹²⁶ Patients with psoriatic disease should be aware that infection with

SARS-CoV-2 may result in a flare of psoriasis, which may occur due to discontinuation of psoriasis treatments, treatment of COVID-19 with antimalarial drugs, or due to triggering of inflammation as part of COVID-19 illness (Guidance 5.6).^{125,127-129}

Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance¹³⁰⁻¹³³ on home isolation and discuss with their health care providers when they can end home quarantine (Guidance 5.7; Supplemental E-Table IX).^{130,134,135} In the event someone with psoriatic disease has close contact (Supplemental E-Table X) with an individual with suspected or confirmed SARS-CoV-2 infection, they should quarantine for 14 days after the last contact, according to CDC guidelines (Guidance 5.8).¹³⁶ The decision regarding continuing or holding psoriasis treatments during a period of quarantine should be individualized on a case-by-case basis between patient and provider.

Resumption of psoriasis or psoriatic arthritis treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis (Guidance 5.5). The persistence of 1 or more symptoms of COVID-19, such as fatigue or joint pain, beyond the acute phase of the illness can occur¹³⁷ and may complicate the decision to restart psoriasis or psoriatic arthritis medications. Therefore, shared decision making is recommended (Guidance 2.5).

DISCUSSION

The NPF COVID-19 TF guidance statements serve to promote optimal management of psoriatic disease

during the pandemic. There are several strengths to the approach taken. First, the TF assembled is a geographically diverse team that has expertise in adult and pediatric dermatology, rheumatology, critical care, infectious diseases, epidemiology, and basic and translational immunology, with experience managing surges in COVID-19. The TF also includes trainees in dermatology, rheumatology, and infectious disease, who are on the frontlines managing patients with COVID-19, as well as senior staff from the NPF who are in touch daily with patients and providers worldwide whose questions are brought to the TF.

Second, we have established a robust process for staying up-to-date with the latest literature relevant to COVID-19 and the management of psoriatic disease resulting in the dissemination and evaluation of hundreds of peer reviewed publications by the TF.

Third, a validated Delphi approach enabled transparency and reproducibility of our process for evaluating consensus statements.²⁵⁻³¹

Several limitations are acknowledged. First, the TF did not formally grade the strength of our recommendations.¹³⁸ With the exception of guidance statements 4.4, 5.2, and 5.4, which are based on large-scale randomized controlled trials, the evidence behind many of the guidance statements was often limited in quality. For example, studies evaluating the safety of treatments for psoriasis and psoriatic arthritis in the setting of COVID-19 involve small case series or large collections of case reports and thus should be considered preliminary. Large-scale, longer-term, population-based studies with appropriate comparator groups, adjustment for relevant confounding variables, and complete ascertainment of clinically important COVID-19 outcomes are urgently needed.

Second, the guidance is not intended to be prescriptive or comprehensive. The ultimate judgment regarding how these recommendations should be followed is best left with the treating clinician and the patient in light of the circumstances presented by the individual patient and the variability and biologic behavior of the disease and therapeutics.

Third, the TF does not have global representation of experts or direct inclusion of patients.

The guidance statements are intended to be part of a “living” document that will be updated and amended when necessary by the rapidly evolving science of COVID-19. Readers are encouraged to visit <https://www.psoriasis.org/covid-19-resource-center> regularly for the latest guidance from the TF in order to promote optimal care and outcomes for patients with psoriatic disease during the pandemic.

The authors thank Monika Goyal, MD, MSCE, for her expert input on guidance statement 4.3.

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020; 382:727-733.
2. Diamond B. The renin-angiotensin system: an integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. *J Exp Med*. 2020:217.
3. Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. *Immunity*. 2020;52: 731-733.
4. Matheson NJ, Lehner PJ. How does SARS-CoV-2 cause COVID-19? *Science*. 2020;369:510-511.
5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382: 1708-1720.
6. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet*. 2020;395:1763-1770.
7. Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes. *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.26424>.
8. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26:1017-1032.
9. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. *Nat Rev Immunol*. 2020;20:389-391.
10. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*. 2020;136:489-500.
11. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 2020;369:718-724.
12. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. *Immunity*. 2020;52: 910-941.
13. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. *Arthritis Rheumatol*. 2020;72:1059-1063.
14. Vaninov N. In the eye of the COVID-19 cytokine storm. *Nat Rev Immunol*. 2020;20:277.
15. Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. *Curr Opin Rheumatol*. 2016;28:204-210.
16. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*. 2020;323: 1945-1960.
17. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med*. 2017;376:957-970.
18. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. *Signal Transduct Target Ther*. 2020;5:84.
19. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol*. 2016;68:1060-1071.
20. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic non-biologic therapies. *J Am Acad Dermatol*. 2020;82:1445-1486.
21. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of

- psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.
22. Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis Rheumatol*. 2019;71:5-32.
23. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. *Curr Opin Rheumatol*. 2015;27:118-126.
24. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. *J Am Acad Dermatol*. 2017;76:377-390.
25. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: version 1. *Arthritis Rheumatol*. 2020;72:1241-1251.
26. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR. The RAND/UCLA Appropriateness Method User's Manual. Rand Corp; 2001.
27. Brook R. US Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care Clinical Practice Guideline Development: Methodology Perspectives. The RAND/UCLA appropriateness method. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1994:59-70.
28. Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE. The reproducibility of a method to identify the overuse and underuse of medical procedures. *N Engl J Med*. 1998;338:1888-1895.
29. Shekelle PG, Chassin MR, Park RE. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. *Int J Technol Assess Health Care*. 1998;14:707-727.
30. Hemingway H, Chen R, Junghans C, et al. Appropriateness criteria for coronary angiography in angina: reliability and validity. *Ann Intern Med*. 2008;149:221-231.
31. Kravitz RL, Laouri M, Kahan JP, et al. Validity of criteria used for detecting underuse of coronary revascularization. *JAMA*. 1995;274:632-638.
32. Costa L, Tasso M, Scotti N, et al. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. *Ann Rheum Dis*. 2020. <https://doi.org/10.1136/annrheumdis-2020-217806>.
33. Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. *Curr Opin Rheumatol*. 2020;32:434-440.
34. Vispi M, Corradin T, Peccianti C, et al. Psoriasis, biological drugs and coronavirus disease 2019: real life experience of two Italian provinces. *Dermatol Rep*. 2020;12:8642.
35. Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. *J Autoimmun*. 2020;112:102502.
36. Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. *N Engl J Med*. 2020;383:85-88.
37. Allocca M, Guidelli GM, Borroni RG, et al. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan. *Pharmacol Res*. 2020;160:105061.
38. Kutlu O, Metin A. Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? *Dermatol Ther*. 2020:e13509.
39. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436.
40. Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? *J Dermatolog Treat*. 2020:1-2.
41. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. *J Invest Dermatol*. 2009;129:2411-2418.
42. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006;296:1735-1741.
43. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. *J Invest Dermatol*. 2012;132:556-562.
44. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J*. 2010;31:1000-1006.
45. Noe MH, Shin DB, Wan MT, Gelfand JM. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. *J Invest Dermatol*. 2018;138:228-230.
46. Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. *Eur Heart J*. 2018;39(39):3608-3614.
47. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis*. 2015;74:326-332.
48. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *BMJ*. 2013;347:f5961.
49. Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. *J Am Acad Dermatol*. 2018;78:315-322.e1.
50. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. *JAMA*. 2020;324(8):799-801.
51. Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID-19. *Heart*. 2020;106:1132-1141.
52. Teague HL, Varghese NJ, Tsoi LC, et al. Neutrophil subsets, platelets, and vascular disease in psoriasis. *JACC Basic Transl Sci*. 2019;4:1-14.
53. Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. *Exp Dermatol*. 2010;19:736-741.
54. Saleh HMA, Attia EAS, Onsy AM, Saad AA, Abd Ellah MMM. Platelet activation: a link between psoriasis per se and subclinical atherosclerosis—a case—control study. *Br J Dermatol*. 2013;169:68-75.
55. Takeshita J, Mohler ER, Krishnamoorthy P, et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. *J Am Heart Assoc*. 2014;3:e000507.

56. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. *J Am Geriatr Soc*. 2020;68:926-929.
57. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-513.
58. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.
59. Centers for Disease Control and Prevention. Am I at Higher Risk for Severe Illness from COVID-19? Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html>. Accessed August 24, 2020.
60. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol*. 2013;149:1173-1179.
61. Pirro F, Caldarola G, Chiricozzi A, et al. The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. *J Dermatolog Treat*. 2020:1-5.
62. Georgakopoulos JR, Mufti A, Vender R, Yeung J. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: a Canadian multicenter retrospective study. *J Am Acad Dermatol*. 2020. <https://doi.org/10.1016/j.jaad.2020.07.021>.
63. Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, et al. Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice. *J Dermatolog Treat*. 2020:1-3.
64. Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM. The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. *J Am Acad Dermatol*. 2020. <https://doi.org/10.1016/j.jaad.2020.06.1014>.
65. Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. *J Am Acad Dermatol*. 2020;83:677-679.
66. Fougerousse AC, Perrussel M, Bécherel PA, et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. *J Eur Acad Dermatol Venereol*. 2020. <https://doi.org/10.1111/jdv.16761>.
67. Wang CJ, Truong AK. COVID-19 infection on IL-23 inhibition. *Dermatol Ther*. 2020:e13893.
68. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. *J Dermatolog Treat*. 2020:1-5.
69. Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. *Dermatol Ther*. 2020:e13961.
70. Di Lernia V, Goldust M, Feliciani C. Covid-19 infection in psoriasis patients treated with cyclosporin. *Dermatol Ther*. 2020:e13739.
71. Olisova OY, Anpilogova EM, Svistunova DA. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient. *Dermatol Ther*. 2020:e13668.
72. Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G. Psoriasis, COVID-19, and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment. *Dermatol Ther*. 2020:e13706.
73. Valenti M, Facheris P, Pavia G, et al. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab. *Dermatol Ther*. 2020:e13708.
74. Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F. Biologic agents in psoriasis: our experience during coronavirus infection. *Int J Dermatol*. 2020;59:e266-e267.
75. Burlando M, Carmisciano L, Cozzani E, Parodi A. A survey of psoriasis patients on biologics during COVID-19: a single centre experience. *J Dermatolog Treat*. 2020:1.
76. Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. *Dermatol Ther*. 2020:e13580.
77. Benhadou F, Del Marmol V. Improvement of SARS-CoV-2 symptoms following guselkumab injection in a psoriatic patient. *J Eur Acad Dermatol Venereol*. 2020;34:e363-e364.
78. Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-9 infection in four psoriatic patients treated with biological drugs. *J Eur Acad Dermatol Venereol*. 2020;34:e360-e361.
79. Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo, Lombardy, Italy. *J Am Acad Dermatol*. 2020;83:292-294.
80. Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. *Br J Dermatol*. 2020;183:373-374.
81. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. *J Am Acad Dermatol*. 2020;83:285-287.
82. Brownstone ND, Thibodeaux QG, Reddy VD, et al. Novel coronavirus disease (COVID-19) and biologic therapy for psoriasis: successful recovery in two patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Dermatol Ther (Heidelb)*. 2020;10:881-885.
83. Facheris P, Valenti M, Pavia G, et al. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. *Int J Dermatol*. 2020;59:e267-e268.
84. Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. *J Eur Acad Dermatol Venereol*. 2020;34:e254-e255.
85. Lima XT, Cueva MA, Lopes EM, Alora MB. Severe COVID-19 outcomes in patients with psoriasis. *J Eur Acad Dermatol Venereol*. 2020. <https://doi.org/10.1111/jdv.16867>.
86. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. *Dermatol Ther*. 2020:e13475.
87. Jovani V, Calabuig I, Peral-Garrido ML, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. *Ann Rheum Dis*. 2020. <https://doi.org/10.1136/annrheumdis-2020-218152>.
88. Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL. Biologics, spondylitis and COVID-19. *Ann Rheum Dis*. 2020. <https://doi.org/10.1136/annrheumdis-2020-217941>.
89. Sharmeen S, Elghawry A, Zarlusht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. *Semin Arthritis Rheum*. 2020;50:680-686.

90. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis*. 2020;79:859.
91. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. *Gastroenterology*. 2020;159(2):481-491.e3.
92. Khan N, Patel D, Xie D, Lewis J, Trivedi C, Yang YX. Impact of anti-TNF and thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide VA cohort study. *Gastroenterology*. 2020. <https://doi.org/10.1053/j.gastro.2020.05.065>.
93. Haberman RH, Castillo R, Chen A, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes. *Arthritis Rheumatol*. 2020. <https://doi.org/10.1002/art.41456>.
94. Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. *J Eur Acad Dermatol Venereol*. 2020;34:1196-1201.
95. Gupta R, Ibrahim MK, Doan HQ. Teledermatology in the wake of COVID-19: advantages and challenges to continued care in a time of disarray. *J Am Acad Dermatol*. 2020;83:168-169.
96. Ranney ML, Griffith V, Jha AK. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic. *N Engl J Med*. 2020;382:e41.
97. Cross C. Social Distancing: Keep On Keeping Your Distance; 2020 Available at: <https://yeswecare.co.za/2020/07/22/social-distancing-keep-on-keeping-your-distance/>. Accessed August 24, 2020.
98. Armstrong AW, Chambers CJ, Maverakis E, et al. Effectiveness of online vs in-person care for adults with psoriasis: a randomized clinical trial. *JAMA Netw Open*. 2018;1:e183062.
99. Armstrong AW, Ford AR, Chambers CJ, et al. Online care versus in-person care for improving quality of life in psoriasis: a randomized controlled equivalency trial. *J Invest Dermatol*. 2019;139:1037-1044.
100. Brunasso AMG, Massone C. Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. *Dermatol Ther*. 2020:e13495.
101. Wood PR, Caplan L. Outcomes, Satisfaction, and costs of a rheumatology telemedicine program: a longitudinal evaluation. *J Clin Rheumatol*. 2019;25:41-44.
102. American Academy of Dermatology. Teledermatology Toolkit. Dermatologists can use telemedicine during COVID-19 outbreak. Available at: <https://www.aad.org/member/practice/telederm/toolkit>. Accessed August 24, 2020.
103. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM. Recommendations for phototherapy during the COVID-19 pandemic. *J Am Acad Dermatol*. 2020;83:287-288.
104. Elmetts CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *J Am Acad Dermatol*. 2019;81:775-804.
105. Centers for Disease Control and Prevention. How to Protect Yourself & Others. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html>; 2020. Accessed August 24, 2020.
106. Raef H, Freeman E, Tan J. Skin care for health care workers during COVID-19. AAD.org: American Academy of Dermatology and the American Academy of Dermatology Association; 2020. https://assets.ctfassets.net/1ny4yoiyrgia/1718wipL9sbOuX42odjjDA/4c5afafa6c3b54853df6df47f2dbed17/20-341-CMM_COVID-19_-_Health_Care_Workers_infographic.pdf. Accessed September 15, 2020.
107. Thiers BH, Tomecki KJ, Taylor SC, et al. Preventing and treating occupationally induced dermatologic conditions during COVID-19. A guide to preventing and treating occupationally induced dermatologic conditions during COVID-19. American Academy of Dermatology. Available at: <https://www.aad.org/public/diseases/coronavirus/occ-induced>. Accessed August 24, 2020.
108. Elmetts M, Craig A, Korman M, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. 2020. <https://doi.org/10.1016/j.jaad.2020.07.087>.
109. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis*. 2018;77:898-904.
110. U.S. Food & Drug Administration. Fact sheet for health care providers: Emergency use authorization (EUA) of Veklury® (remdesivir). Available at: <https://www.fda.gov/media/137566/download>; 2020. Accessed August 24, 2020.
111. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2007764>.
112. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2021436>.
113. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? *J Eur Acad Dermatol Venereol*. 2013;27:1022-1025.
114. U.S. Food & Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxy-chloroquine-or-chloroquine-covid-19-outside-hospital-setting-or>; 2020. Accessed August 24, 2020.
115. U.S. Food & Drug Administration. Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate. Available at: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and>; 2020. Accessed August 24, 2020.
116. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciaa478>.
117. National Institutes of Health. Coronavirus Disease (COVID-19) treatment guidelines; 2020 Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed August 24, 2020.
118. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Humphrey LL. Update alert 2: should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living Practice Points From the American College of Physicians. *Ann Intern Med*. 2020;173(5):W88-W89.

119. Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—an observational study. *PLoS One*. 2020;15(8):e0237693.
120. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *JAMA*. 2020;323:2493-2502.
121. Sbidian E, Josse J, Lemaitre G, et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France [preprint]. *medRxiv*. 2020. <https://doi.org/10.1101/2020.06.16.20132597>.
122. Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial [preprint]. *medRxiv*. 2020. <https://doi.org/10.1101/2020.07.15.20151852>.
123. National Institutes of Health. NIH halts clinical trial of hydroxychloroquine. Available at: <https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine>; 2020. Accessed August 24, 2020.
124. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>; 2020. Accessed August 24, 2020.
125. Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic? *Dermatol Ther*. 2020:e13383.
126. Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J. Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment. *J Am Acad Dermatol*. 2020;83:579-586.
127. Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O. A case of severe psoriatic erythroderma with COVID-19. *J Dermatolog Treat*. 2020;1-3.
128. Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid-19 and exacerbation of psoriasis. *Dermatol Ther*. 2020:e13632.
129. Gananandan K, Sacks B, Ewing I. Guttate psoriasis secondary to COVID-19. *BMJ Case Rep*. 2020;13.
130. Centers for Disease Control and Prevention. Discontinuation of isolation for persons with COVID-19 not in healthcare settings. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html>; 2020. Accessed August 24, 2020.
131. Centers for Disease Control and Prevention. Duration of isolation and precautions for adults with COVID-19. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>; 2020. Accessed August 24, 2020.
132. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N Engl J Med*. 2020;382:2081-2090.
133. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciaa638>.
134. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants [preprint]. *medRxiv*. 2020. <https://doi.org/10.1101/2020.06.08.20125310>.
135. Brooks JT, Butler JC, Redfield RR. Universal masking to prevent SARS-CoV-2 transmission—the time is now. *JAMA*. 2020;324(7):635-637.
136. Centers for Disease Control and Prevention. When to quarantine. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html>; 2020. Accessed August 24, 2020.
137. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA*. 2020;324(6):603-605.
138. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011; 64:383-394.